Gastrointestinal Stromal Tumors Pipeline Analysis, Clinical Trials, EMA, PDMA, FDA Approval, Therapies, Medication, Treatment Market, MOA, ROA, Companies by DelveInsight

(Albany, USA) DelveInsight's, "Gastrointestinal Stromal Tumors Pipeline Insight" report provides comprehensive insights about 25+ companies and 28+ pipeline drugs in Gastrointestinal Stromal Tumors (GIST) pipeline landscape. The report covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Gastrointestinal Stromal Tumors Pipeline. Dive into DelveInsight's comprehensive report today! @ Gastrointestinal Stromal Tumors Pipeline Outlook- https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the Gastrointestinal Stromal Tumors Pipeline Report
• In November 2024:- Merck Sharp & Dohme LLC- A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic Alterations
• In November 2024:- Deciphera Pharmaceuticals LLC-This is a Phase 1/2, multicenter, open-label (unless otherwise specified in a combination-specific module) study of DCC-3116 in combination with anticancer therapies. Modules within the master protocol are defined according to different combinations of DCC-3116 with other anticancer agents.
• In November 2024:- Travera Inc.- The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from various specimen formats including malignant fluids such as pleural effusions and ascites, core needle biopsies, fine needle aspirates, or resections.
• DelveInsight's Gastrointestinal Stromal Tumors Pipeline analysis depicts a robust space with 25+ active players working to develop 28+ pipeline treatment therapies.
• The leading Gastrointestinal Stromal Tumors Companies such as Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, Chia Tai Tianqing Pharmaceutical Group, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, GlaxoSmithKline, Ascentage Pharma, Takeda, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx, Inc., Allarity Therapeutics, and others.
• Promising Gastrointestinal Stromal Tumors Therapies such as Belzutifan, Sunitinib, CGT9486, DCC-3116, Ripretinib, UCB4594, and others.

Stay ahead with the most recent pipeline outlook for Gastrointestinal Stromal Tumors. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Gastrointestinal Stromal Tumors Approved Drugs- https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Gastrointestinal Stromal Tumors (GIST) Emerging Drugs

• Famitinib: Jiangsu Hengrui Medicine
Famitinib, an orally active, small molecule, is a tyrosine kinase inhibitor against multiple targets, including vascular endothelial growth factor receptor 2/3, platelet-derived growth factor receptor, and stem cell factor receptor (c-kit). Jiangsu Hengrui Medicine Co is developing famitinib against a wide variety of advanced-stage solid cancers. The drug is currently in phase 3 of clinical development for the treatment of Gastrointestinal Stromal Tumors (GIST).

• Nilotinib: Novartis
Tasigna (nilotinib hydrochloride monohydrate) is an orally available signal transduction inhibitor of the Bcr-Abl kinase, c-kit and Platelet Derived Growth Factor (PDGF), all of which play a role in cell proliferation, cell migration, and angiogenesis. Tasigna is specifically indicated for the treatment of chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (CML) in adult patients resistant or intolerant to prior therapy that included imatinib. The drug is currently being investigated in Phase II clinical trial to evaluate its potential for the treatment of gastrointestinal stromal tumors.

• THE-630: Theseus Pharmaceuticals
THE-630 is a pan-variant inhibitor of the receptor tyrosine kinase KIT. It is designed for patients with advanced GIST whose cancer has developed resistance to earlier lines of therapy by accruing mutations that render those therapies ineffective. In GIST, these mutations occur most often in the KIT protein, where a patient can have multiple KIT mutations simultaneously, leading to complex disease heterogeneity. In preclinical studies, THE-630 demonstrated potent in vitro and in vivo activity against all major classes of KIT activating and resistance mutations in GIST. Moreover, THE-630 achieved predicted pan-variant KIT inhibitory blood concentrations at tolerable doses and was associated with significant anti-tumor activity. Theseus Pharmaceuticals is currently conducting Phase I/II study to evaluate lead candidate, THE-630, in patients with advanced gastrointestinal stromal tumors (GIST).

• DS 6157: Daiichi Sankyo Company
DS-6157 is a potential first-in-class GPR20 targeting ADC and the fifth DXd ADC in the oncology pipeline of Daiichi Sankyo to enter clinical development. ADCs are targeted cancer medicines that deliver cytotoxic chemotherapy ("payload") to cancer cells via a linker attached to a monoclonal antibody that binds to a specific target expressed on cancer cells. Designed utilizing Daiichi Sankyo's proprietary DXd ADC technology, DS-6157 is comprised of a humanized anti-GPR20 monoclonal antibody, which is attached to a novel topoisomerase I inhibitor payload by a tetrapeptide-based linker. The drug is currently in Phase I stage of clinical trial evaluation to treat Gastrointestinal Stromal Tumors.

Explore groundbreaking therapies and clinical trials in the Gastrointestinal Stromal Tumors Pipeline. Access DelveInsight's detailed report now! @ Gastrointestinal Stromal Tumors Treatment Drugs https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Gastrointestinal Stromal Tumors Companies
Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, Chia Tai Tianqing Pharmaceutical Group, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, GlaxoSmithKline, Ascentage Pharma, Takeda, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx, Inc., Allarity Therapeutics, and others.

Gastrointestinal Stromal Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Gastrointestinal Stromal Tumors Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Unveil the future of Gastrointestinal Stromal Tumors Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Gastrointestinal Stromal Tumors Market Drivers and Barriers- https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Gastrointestinal Stromal Tumors Pipeline Report
• Coverage- Global
• Gastrointestinal Stromal Tumors Companies- Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, Chia Tai Tianqing Pharmaceutical Group, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, GlaxoSmithKline, Ascentage Pharma, Takeda, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx, Inc., Allarity Therapeutics, and others.
• Gastrointestinal Stromal Tumors Therapies- Belzutifan, Sunitinib, CGT9486, DCC-3116, Ripretinib, UCB4594, and others.
• Gastrointestinal Stromal Tumors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Gastrointestinal Stromal Tumors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Gastrointestinal Stromal Tumors Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Gastrointestinal Stromal Tumors Companies, Key Products and Unmet Needs- https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content
1. Introduction
2. Executive Summary
3. Gastrointestinal Stromal Tumors: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Gastrointestinal Stromal Tumors - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Famitinib: Jiangsu Hengrui Medicine
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Nilotinib: Novartis
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. DS 6157: Daiichi Sankyo Company
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Gastrointestinal Stromal Tumors Key Companies
18. Gastrointestinal Stromal Tumors Key Products
19. Gastrointestinal Stromal Tumors- Unmet Needs
20. Gastrointestinal Stromal Tumors- Market Drivers and Barriers
21. Gastrointestinal Stromal Tumors- Future Perspectives and Conclusion
22. Gastrointestinal Stromal Tumors Analyst Views
23. Gastrointestinal Stromal Tumors Key Companies
24. Appendix

Trending Report:
• Bk Virus Infection Market: https://www.delveinsight.com/report-store/bk-virus-bkv-infection-market
• Bone And Joint Infection Market: https://www.delveinsight.com/report-store/prosthetic-joint-infection-market
• Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/bradycardia-treatment-devices-market
• Brain Cancer Market: https://www.delveinsight.com/report-store/brain-cancer-market
• Brain/cranial Implants Market: https://www.delveinsight.com/report-store/brain-implants-market-market
• Cardiac Amyloidosis Market: https://www.delveinsight.com/report-store/cardiac-amyloidosis-market
• Cardiac Restoration Systems Market: https://www.delveinsight.com/report-store/cardiac-restoration-systems-market
• Central Venous Catheters Market: https://www.delveinsight.com/report-store/central-venous-catheters-market
• Centronuclear Myopathy Market: https://www.delveinsight.com/report-store/centronuclear-myopathy-cnm-pipeline-insight
• Cervical Dystonia Market: https://www.delveinsight.com/report-store/cervical-dystonia-market
• Choroidal Neovascularization Market: https://www.delveinsight.com/report-store/choroidal-neovascularization-market
• Chronic Inflammtory Demyelinating Polyneuropathy Market: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
• Chronic Lymphocytic Leukemia Market: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-market
• Chronic Refractory Gout Market: https://www.delveinsight.com/report-store/chronic-refractory-gout-market
• Competitive Intelligence Pharma: https://www.delveinsight.com/blog/competitive-intelligence-in-healthcare-sector
• Corneal Endothelial Dystrophy Market: https://www.delveinsight.com/report-store/corneal-endothelial-dystrophy-market
• Ctcl Market: https://www.delveinsight.com/report-store/cutaneous-t-cell-lymphoma-ctcl-market
• Diabetic Neuropathy Market: https://www.delveinsight.com/report-store/diabetic-peripheral-neuropathy-market
• Duchenne Muscular Dystrophy Market: https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-market
• Endometriosis Pain Market: https://www.delveinsight.com/report-store/endometriosis-pain-market
• Endoscopy Fluid Management Systems Market: https://www.delveinsight.com/blog/endoscopy-fluid-management-systems-market
• Epidermolysis Bullosa Market: https://www.delveinsight.com/report-store/epidermolysis-bullosa-market
• Exocrine Pancreatic Insufficiency Market: https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-epi-market
• Facioscapulohumeral Muscular Dystrophy Market: https://www.delveinsight.com/report-store/facioscapulohumeral-muscular-dystrophy-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/
Case Study: https://www.delveinsight.com/case-study/conference-intelligence-product-assessment

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.